PDF(Pubmed)
Abstract：
UNASSIGNED: This report aims to highlight the wide spectrum of ophthalmic adverse events associated with erdafitinib, a fibroblast growth factor inhibitor that blocks activation of the mitogen-activated protein kinase kinase (MAPK/MEK) cascade. The purpose of this report is to describe a case of erdafitinib-associated bilateral outer retinal alterations in the MEK-associated retinopathy spectrum and rapid onset bilateral total cataracts following a 20-month course of erdafitinib therapy.
UNASSIGNED: A 69 year old male with metastatic bladder cancer presented 47 days following treatment initiation with daily erdafitinib (8-mg) with mild new subretinal fluid and minimal associated subretinal debris in the left eye and accentuation/thickening of the interdigitation zone in the right eye. Over the course of treatment, improvements were noted, particularly with erdafitinib dose reduction. At 20 months, both eyes developed rapidly progressive mature cataracts with significant visual changes, necessitating bilateral cataract extraction.
UNASSIGNED: The potential stability of moderate outer retinal changes (i.e., ellipsoid zone/interdigitation zone, subretinal fluid) while continuing erdafitinib therapy is highlighted in this report. In addition, the importance of continued ophthalmic surveillance is emphasized given the possible association of anterior segment adverse events with long-term erdafitinib use.
UNASSIGNED: A 69 year old male with metastatic bladder cancer presented 47 days following treatment initiation with daily erdafitinib (8-mg) with mild new subretinal fluid and minimal associated subretinal debris in the left eye and accentuation/thickening of the interdigitation zone in the right eye. Over the course of treatment, improvements were noted, particularly with erdafitinib dose reduction. At 20 months, both eyes developed rapidly progressive mature cataracts with significant visual changes, necessitating bilateral cataract extraction.
UNASSIGNED: The potential stability of moderate outer retinal changes (i.e., ellipsoid zone/interdigitation zone, subretinal fluid) while continuing erdafitinib therapy is highlighted in this report. In addition, the importance of continued ophthalmic surveillance is emphasized given the possible association of anterior segment adverse events with long-term erdafitinib use.
摘要：
■本报告旨在强调与erdafitinib相关的广泛眼科不良事件，一种阻断丝裂原活化蛋白激酶激酶（MAPK/MEK）级联激活的成纤维细胞生长因子抑制剂。本报告的目的是描述一例在20个月疗程的erdafitinib治疗后，MEK相关视网膜病变谱中与erdafitinib相关的双侧外视网膜改变和快速发作的双侧总白内障。
■一名69岁男性转移性膀胱癌患者在开始每日服用erdafitinib（8mg）治疗后47天出现，左眼出现轻度新的视网膜下液和最小的相关视网膜下碎片，右眼交叉带加重/增厚。在治疗过程中，注意到改进，特别是erdafitinib剂量减少。20个月时,两只眼睛发展迅速进行性成熟的白内障，具有显著的视觉变化，需要双侧白内障摘除术。
■中度外部视网膜变化的潜在稳定性（即，椭圆体区/叉指区,视网膜下液），同时继续erdafitinib治疗在本报告中强调。此外,鉴于眼前节不良事件可能与长期使用erdafitinib相关,因此强调了持续眼科监测的重要性.
■一名69岁男性转移性膀胱癌患者在开始每日服用erdafitinib（8mg）治疗后47天出现，左眼出现轻度新的视网膜下液和最小的相关视网膜下碎片，右眼交叉带加重/增厚。在治疗过程中，注意到改进，特别是erdafitinib剂量减少。20个月时,两只眼睛发展迅速进行性成熟的白内障，具有显著的视觉变化，需要双侧白内障摘除术。
■中度外部视网膜变化的潜在稳定性（即，椭圆体区/叉指区,视网膜下液），同时继续erdafitinib治疗在本报告中强调。此外,鉴于眼前节不良事件可能与长期使用erdafitinib相关,因此强调了持续眼科监测的重要性.
